Moderna, Inc.
MRNA
Helyezés a részvények között
#228
Moderna, Inc., a biotechnology firm, is dedicated to the discovery,... Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
Részvényárfolyam
$251.29
Piaci kapitalizáció
$100.32B
Változás (1 nap)
3.80%
Változás (1 év)
814.11%
Ország
US
Kereskedés Moderna, Inc. (MRNA)
Kategória
Healthcare
Bevétel a(z) Moderna, Inc. (MRNA) részvényhez
Bevétel ekkor: Jun 2026 TTM: $2.23B
Moderna, Inc. legfrissebb pénzügyi jelentései szerint a vállalat jelenlegi árbevétele (TTM) $2.23B. 2024 évben a vállalat $3.20B árbevételt ért el, amely csökkenés a 2023 évben elért $6.85B árbevételhez képest. Az árbevétel az a teljes összeg, amit a vállalat termékek vagy szolgáltatások eladásából generál. A nyereséggel ellentétben ebből nem vonódnak le költségek.
Moderna, Inc. bevételtörténete 2016 és 2026 között
Bevétel az év végén
| Év | Bevétel | Változtassa meg |
|---|---|---|
| 2026 (TTM) | $2.23B | 14.61% |
| 2025 | $1.94B | -39.23% |
| 2024 | $3.20B | -53.29% |
| 2023 | $6.85B | -63.72% |
| 2022 | $18.88B | 6.42% |
| 2021 | $17.74B | 2,107.63% |
| 2020 | $803.40M | 1,234.34% |
| 2019 | $60.21M | -55.42% |
| 2018 | $135.07M | -34.38% |
| 2017 | $205.83M | 89.88% |
| 2016 | $108.40M | 0.00% |
Hasonló cégek vagy versenytársak bevétele
| Vállalat | Bevétel | Bevételkülönbség | Ország |
|---|---|---|---|
| $12.62B | 466.62% |
US
|
|
| $15.74B | 606.66% |
AU
|
|
| $6.02B | 170.26% |
NL
|
|
| - | - |
CH
|
|
| $10.11B | 353.81% |
BE
|
